CN101239037A - Acetylcysteine injection and preparation thereof - Google Patents
Acetylcysteine injection and preparation thereof Download PDFInfo
- Publication number
- CN101239037A CN101239037A CNA200810085531XA CN200810085531A CN101239037A CN 101239037 A CN101239037 A CN 101239037A CN A200810085531X A CNA200810085531X A CN A200810085531XA CN 200810085531 A CN200810085531 A CN 200810085531A CN 101239037 A CN101239037 A CN 101239037A
- Authority
- CN
- China
- Prior art keywords
- acetylcysteine
- injection
- solution
- acetylcysteine injection
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 229940021715 acetylcysteine injection Drugs 0.000 title claims description 46
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 63
- 229960004308 acetylcysteine Drugs 0.000 claims abstract description 51
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960000281 trometamol Drugs 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 43
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 230000001681 protective effect Effects 0.000 claims description 10
- 229940090044 injection Drugs 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 239000003172 expectorant agent Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 230000003204 osmotic effect Effects 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000011260 aqueous acid Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 206010070834 Sensitisation Diseases 0.000 abstract description 6
- 230000008313 sensitization Effects 0.000 abstract description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 34
- 210000004204 blood vessel Anatomy 0.000 description 26
- 229960003180 glutathione Drugs 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- 206010030113 Oedema Diseases 0.000 description 13
- 210000003743 erythrocyte Anatomy 0.000 description 13
- 208000007536 Thrombosis Diseases 0.000 description 12
- 230000007850 degeneration Effects 0.000 description 12
- 230000008595 infiltration Effects 0.000 description 12
- 238000001764 infiltration Methods 0.000 description 12
- 210000003556 vascular endothelial cell Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 8
- 235000011121 sodium hydroxide Nutrition 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 6
- 229960003067 cystine Drugs 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000004158 L-cystine Substances 0.000 description 4
- 235000019393 L-cystine Nutrition 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 239000008354 sodium chloride injection Substances 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- RGWPPSAULBHMAA-NXEZZACHSA-N (2r)-2-amino-2-[[[(2r)-2-amino-2-carboxy-3-oxobutyl]disulfanyl]methyl]-3-oxobutanoic acid Chemical compound CC(=O)[C@@](N)(C(O)=O)CSSC[C@@](N)(C(C)=O)C(O)=O RGWPPSAULBHMAA-NXEZZACHSA-N 0.000 description 3
- 239000004201 L-cysteine Substances 0.000 description 3
- 235000013878 L-cysteine Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000283977 Oryctolagus Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000003969 glutathione Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- UIQKZVQFTHWEGC-FHNDMYTFSA-M sodium (2R)-2-acetamido-3-sulfanylpropanoic acid chloride Chemical compound [Na+].[Cl-].CC(=O)N[C@@H](CS)C(O)=O UIQKZVQFTHWEGC-FHNDMYTFSA-M 0.000 description 2
- ROBLTDOHDSGGDT-UHFFFAOYSA-M sodium;pentane-1-sulfonate Chemical compound [Na+].CCCCCS([O-])(=O)=O ROBLTDOHDSGGDT-UHFFFAOYSA-M 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102100034294 Glutathione synthetase Human genes 0.000 description 1
- 101710101434 Glutathione synthetase Proteins 0.000 description 1
- 101710087514 Glutathione synthetase, chloroplastic Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000005261 decarburization Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- -1 oxygen free radical Chemical class 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810085531XA CN101239037B (en) | 2008-03-17 | 2008-03-17 | Acetylcysteine injection and preparation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810085531XA CN101239037B (en) | 2008-03-17 | 2008-03-17 | Acetylcysteine injection and preparation thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101239037A true CN101239037A (en) | 2008-08-13 |
CN101239037B CN101239037B (en) | 2010-12-22 |
Family
ID=39931055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200810085531XA Expired - Fee Related CN101239037B (en) | 2008-03-17 | 2008-03-17 | Acetylcysteine injection and preparation thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101239037B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102514755A (en) * | 2011-11-04 | 2012-06-27 | 蚌埠丰原涂山制药有限公司 | Preparation method of xantinol nicotinate and sodium chloride injection packaged by using soft bag |
CN114681397A (en) * | 2020-12-26 | 2022-07-01 | 四川汇宇制药股份有限公司 | Preparation method of acetylcysteine injection |
US11413238B2 (en) | 2020-02-18 | 2022-08-16 | Endo Ventures Limited | N-acetylcysteine compositions and methods |
CN115266963A (en) * | 2022-06-01 | 2022-11-01 | 北京诺康达医药科技股份有限公司 | Method for detecting cysteine and cystine in compound amino acid injection |
-
2008
- 2008-03-17 CN CN200810085531XA patent/CN101239037B/en not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102514755A (en) * | 2011-11-04 | 2012-06-27 | 蚌埠丰原涂山制药有限公司 | Preparation method of xantinol nicotinate and sodium chloride injection packaged by using soft bag |
US11413238B2 (en) | 2020-02-18 | 2022-08-16 | Endo Ventures Limited | N-acetylcysteine compositions and methods |
US11752097B2 (en) | 2020-02-18 | 2023-09-12 | Endo Ventures Limited | N-acetylcysteine compositions and methods |
CN114681397A (en) * | 2020-12-26 | 2022-07-01 | 四川汇宇制药股份有限公司 | Preparation method of acetylcysteine injection |
CN115266963A (en) * | 2022-06-01 | 2022-11-01 | 北京诺康达医药科技股份有限公司 | Method for detecting cysteine and cystine in compound amino acid injection |
CN115266963B (en) * | 2022-06-01 | 2024-01-05 | 北京诺康达医药科技股份有限公司 | Method for detecting cysteine and cystine in compound amino acid injection |
Also Published As
Publication number | Publication date |
---|---|
CN101239037B (en) | 2010-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8835508B2 (en) | Stable aqueous solution containing sodium pyruvate, and the preparation and use thereof | |
EP2307056B1 (en) | Stabilized aqueous formulation containing paracetamol | |
CN101239037B (en) | Acetylcysteine injection and preparation thereof | |
WO2013144814A1 (en) | Stable ready-to-use pharmaceutical composition of pemetrexed | |
CN106692124A (en) | Acetylcysteine pharmaceutical composition and preparation method thereof | |
CA3035951A1 (en) | Pharmaceutical preparation containing polyethylene gylcol loxenatide and preparation method thereof | |
US20220096414A1 (en) | Levothyroxine liquid formulations | |
CN104840418A (en) | Fasudil hydrochloride injection composition and preparation method thereof | |
CN103110640B (en) | Pharmaceutical composition of injection ceftizoxime sodium and compound amino acid injection | |
CN101791315B (en) | Compound monoammonium glycyrrhizinate S pharmaceutical composition and method for preparing high-capacity injection | |
WO2020248648A1 (en) | Ornidazole injection and s-ornidazole injection | |
CN107949374A (en) | Stable hyperglycemic factor solution | |
CN104906585A (en) | Oxiracetam high-capacity injection composition and preparing method thereof | |
CN102204908B (en) | Pharmaceutical composition containing edaravone compound, and preparation method thereof | |
CN102988358A (en) | Compound amino acid injection (18AA-IV) composition | |
CN103784438B (en) | A kind of Amino Acid Compound Injection-HBC composition and method of making the same | |
WO2020160123A1 (en) | Levothyroxine liquid formulations | |
CN103463094B (en) | Medicine composition of cefpiramide sodium and infant compound amino acid injection (19AA-I) | |
US20230201197A1 (en) | Hydralazine compositions and methods | |
KR20110037444A (en) | Injectable pharmaceutical formulation | |
CN107737099B (en) | A kind of highly-safe L-ornidazole injection liquid and preparation method thereof | |
WO2006095844A1 (en) | Pharmaceutical preparation | |
CN105267159A (en) | Matrine freeze-dried powder injection and preparation method thereof | |
UA136549U (en) | READY-MADE MEDICINAL PRODUCT FOR TREATMENT OF HYPERAMONYEMIC CONDITIONS | |
CN103446159B (en) | Pharmaceutical composition containing pediatric compound amino acid injection and cefotiam hydrochloride |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20091023 Address after: 813, room 388, Qianjiang science and technology building, Xihu District Wensanlu Road, Hangzhou, Zhejiang, China Post Code: 310012 Applicant after: Hangzhou Sheng You Pharmaceutical Technology Development Co., Ltd. Co-applicant after: Hangzhou Shengyou Medicine Technology Development Co., Ltd. Address before: 813, Qianjiang science and technology building, No. 388, Wensanlu Road, Zhejiang, Hangzhou 310012, China Applicant before: Hangzhou Shengyou Medicine Technology Development Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI GUOCHUANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HANGZHOU SHENGYOU MEDICINE TECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20100513 Free format text: FORMER OWNER: SHANGHAI GUOCHUANG PHARMACEUTICAL CO., LTD. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310012 ROOM 813, QIANJIANG TECHNOLOGY BUILDING, NO.388, WENSAN ROAD, XIHU DISTRICT, HANGZHOU CITY, ZHEJIANG PROVINCE TO: 201203 ROOM 305-17, NO.665, ZHANGJIANG ROAD, PUDONG NEW DISTRICT, SHANGHAI |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20100513 Address after: 201203, room 665, 305-17 Zhangjiang Road, Shanghai, Pudong New Area Applicant after: Hangzhou Shengyou Medicine Technology Development Co., Ltd. Address before: 310012 room 813, Qianjiang science and technology building, No. 388, Xihu District, Zhejiang, Hangzhou, Wensanlu Road Applicant before: Hangzhou Shengyou Medicine Technology Development Co., Ltd. Co-applicant before: Hangzhou Shengyou Medicine Technology Development Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101222 Termination date: 20180317 |
|
CF01 | Termination of patent right due to non-payment of annual fee |